AM Best Withdraws Credit Ratings of Blue Cross Life Insurance Company of Canada
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the…
News
Consumers Shifting Back to Used Vehicles as Inventory Shortages Continue
As used originations increase, credit unions reach nearly 26% total vehicle financing market share, the…
How cloud computing turned security on its head
Josh Stella examines how organizations must adapt to the ever-changing cloud security threat landscape FREDERICK,…
Baptist Health South Florida Adopts the Innovaccer Health Cloud to Drive Population Health Analytics and Provider Engagement
Internationally renowned health system to unify data across systems to improve access to healthcare in…
Strategy Analytics: Electric Vehicles Powertrain Systems Market Accelerates Past $100 Billion
Battery Electric Vehicles to Fuel Growth BOSTON–(BUSINESS WIRE)–The push to electric vehicles is being dictated…
Genius Sports Agrees to Official Data, Trading and Live Streaming Partnership with Bally’s Interactive
Major new agreement to power Bally’s Interactive brands with market-leading data and streaming solutions Genius…
Redgate welcomes Microsoft as the Premier Sponsor of PASS Data Community Summit 2022
Redgate Software announced today that Microsoft will be the Premier Sponsor of the 2022 PASS…
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference
Sofwave to host showcase booth from September 1-4 Facial and neck treatment workshop held on…
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a…
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients…
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The…
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision…
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide,…
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth…
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies,…
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune…
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission…
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing…
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…